Latest Pharmaceuticals News

Bluechiip Limited advances its strategic repositioning with a new licensing agreement valued up to USD 750,000 alongside ongoing efforts to lift its trading suspension and grow sales.

Zelira Therapeutics has secured a fourth funding tranche of US$681,000, advancing its HOPE® Autism Spectrum Disorder FDA trial process and bringing total funding to US$3.25 million. The company is progressing clinical validation and product development, including the transformation of Zenivol® into a capsule formulation.

Amplia Therapeutics reports encouraging progress in its Phase 2a ACCENT trial for pancreatic cancer, with nine confirmed partial responses and ongoing patient recruitment. The company also strengthens its financial position with a $13 million capital raise to support further clinical development.

Argenica Therapeutics has dosed 80% of patients in its Phase 2 stroke trial and gained FDA orphan drug designations for its second candidate, ARG-006. The company reports a cash-positive quarter with $15 million in reserves.

Acrux Limited has launched its Nitroglycerin 0.4% Ointment and successfully raised nearly $4 million, positioning the specialty pharma company for sustained revenue growth.

LTR Pharma reports compelling clinical results for its nasal spray ED treatment SPONTAN®, demonstrating rapid absorption and strong safety, alongside strategic partnerships and a robust $34 million cash position.

Island Pharmaceuticals reports promising safety and anti-dengue activity in its Phase 2a trial of ISLA-101 and has commenced the Phase 2b therapeutic arm, backed by a fresh A$3.5 million capital raise.

MedAdvisor Limited reported a significant 38.6% drop in 2Q FY25 revenue due to vaccine program deferrals but expects a stronger second half driven by a diversified US pipeline and cost-saving initiatives.

Clever Culture Systems Ltd has achieved a key cashflow break-even milestone in Q4 2024, driven by strong sales growth from major pharmaceutical clients including AstraZeneca and Bristol Myers Squibb. The company is also advancing its product line with a new APAS® Contact Plate capability set for mid-2025 launch.

Sigma Healthcare has achieved unanimous shareholder approval for its proposed merger with Chemist Warehouse, marking a pivotal step toward reshaping Australia's pharmaceutical retail landscape. The merger now awaits final court approval, with implementation anticipated in mid-February 2025.

Sigma Healthcare has successfully passed all key resolutions at its extraordinary general meeting, clearing a major hurdle for its proposed merger with Chemist Warehouse. The deal now awaits final court approval, with implementation expected in February.

Algorae Pharmaceuticals reports robust progress in its drug development pipeline, highlighted by promising preclinical results for cardiovascular and dementia candidates and significant AI platform enhancements.